Drug-labels.com

NTP-Hydrochlorothiazide: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx) Current status: Cancelled Pre Market
Strength:
25 mg, 50 mg
Active ingredient:

Patient Medication Information: uses, side effects, how to take - NTP-Hydrochlorothiazide

ABOUT THIS MEDICATION

What the medication is used for:

NTP-HYDROCHLOROTHIAZIDE has been prescribed to you for edema (swelling) associated with heart failure, cirrhosis of the liver, corticosteroid and estrogen therapy and for edema originating from the kidneys; or hypertension; or toxemia (hypertension) due to pregnancy.

What it does:

NTP-HYDROCHLOROTHIAZIDE elevates the rate of urine secretion and lowers blood pressure. Hydrochlorothiazide affects the kidneys ability to reabsorb electrolytes. It increases excretion of sodium and chloride in approximately equivalent amounts and reduces the rate of formation of solute-free water.

When it should not be used:

You should not use NTP-

HYDROCHLOROTHIAZIDE if you:

  • are allergic to Hydrochlorothiazide or to other

    sulfonamide-derived drugs.

  • are allergic to any of the other ingredients in

    the product (please see “What the nonmedicinal ingredients are”)

  • have no production of urine.
  • experience an increase of urea or creatinine

    and a decrease in urine production during treatment of severe progressive kidney disease.

Stop taking the drug and contact your doctor immediately if you experience an allergic reaction or any severe or unusual side effects.

What the medicinal ingredient is:

Hydrochlorothiazide.

What the nonmedicinal ingredients are: colloidal silicon dioxide, FD&C Yellow #6, lactose, magnesium stearate, microcrystalline cellulose and sodium starch glycolate.

What dosage forms it comes in:

Tablets: 25 mg & 50 mg

WARNINGS AND PRECAUTIONS

Before you use NTP-HYDROCHLOROTHIAZIDE talk to your doctor or pharmacists if:

  • If you are taking enteric-coated potassium salts
  • If you have impaired liver function or progressive liver disease
  • If you have impaired kidney function
  • If you are taking anti-hypertensive medication or other adrenergic blocking drugs.
  • If you have a history of sensitivity reactions or a history of allergic reactions to this or other medications
  • If you have lupus

Remember to keep this and other medications away from children.

Tell your physician or pharmacist all medication you are taking, including any non-prescription or herbal medicines.

Other precautions:

Do not take NTP-HYDROCHLOROTHIAZIDE if you are:

  • pregnant or breast-feeding.
  • are allergic to any of its ingredients.

INTERACTIONS WITH THIS MEDICATION

Drugs that may interact with NTP-

HYDROCHLOROTHIAZIDE include:

  • Lithium. Concomitant therapy with lithium is not recommended with NTP-HYDROCHLOROTHIAZIDE because of the reduction of kidney clearance of lithium and therefore an added risk of lithium toxicity.
  • Orthostatic hypotension (low blood pressure while you are standing) may occur and may be enhanced by alcohol, barbiturates, or narcotics

16

You should always tell your physician about all drugs you are taking, including those obtained without a prescription.

PROPER USE OF THIS MEDICATION

Take this medicine exactly as prescribed by your physician.

Adult patients

Diuresis

The recommended adult dosage is 50 mg to 100 mg once or twice a day. Many patients respond to intermittent therapy, i.e. administration on alternate days or on three to five days each week.

Toxemia of pregnancy

The recommended dosage is 100 mg daily or, in severe cases and for brief periods, 200 mg daily (in divided doses). Frequency of administration may range from once every four days to daily.

Premenstrual tension with swelling

The recommended dosage is 25mg to 50 mg once or twice a day from the first appearance of symptoms until onset of the menses.

Control of Hypertension

The usual recommended starting dosage is 50 or 100 mg a day as a single or divided dose. Dosage is increased or decreased according to the blood pressure response of the patient. Some patients may require doses of 200 mg a day in divided doses.

Infants and Children

The usual recommended pediatric dosage is based on 1.0 mg of NTP-HYDROCHLOROTHIAZIDE per pound of body weight per day in two doses. Infants under 6 months of age may require up to 1.5 mg per pound per day in two doses.

On this basis, infants up to 2 years of age may be given 12.5 to 37.5 mg daily in two doses.

The 25 mg tablet can not be divided into quarters.

Overdose:

If you take too many doses, call your

physician immediately.

Missed Dose:

If you miss a dose, and it is close to the next scheduled dose, take your medicine at the next scheduled time. Do NOT double dose.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Gastrointestinal system: Decreased appetite, gastric irritation, nausea, vomiting, cramps, diarrhea, constipation, jaundice (intrahepatic cholestatic jaundice), inflammation of the pancreas, inflammation or enlargement of salivary glands. Central nervous system: Dizziness, a feeling that you or your surroundings are moving, sensation of tingling or numbness, headache, impaired sense of sight.

Hematologic: Leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia.

Cardiovascular: postural hypotension (may be aggravated by alcohol, barbiturates, or narcotics). Hypersensitivity: spontaneous bleeding under the skin, sensitivity to light , rash, red patches on the skin, fever, respiratory distress including pneumonitis, anaphylactic reactions.

Other: Hyperglycemia, muscle spasm, weakness, restlessness, transient blurred vision.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN, AND WHAT TO DO ABOUT THEM

This is not a complete list of side effects. If you have any unexpected effects while taking this drug, contact your doctor or pharmacist.

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

17

HOW TO STORE IT

  • Store at controlled room temperature, 15°- 30°C.
  • Keep out of the reach and sight of children.
  • Do not use after the expiry date indicated on the package.
  • Protect from heat and light.

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

Report online at www.healthcanada.gc.ca/medeffect Call toll-free at 1-866-234-2345

Complete a Canada Vigilance Reporting Form and:

  • Fax toll-free to 1-866-678-6789, or
  • Mail to:

    Canada Vigilance Program

    Health Canada

    Postal Locator 0701E

    Ottawa, Ontario

    K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be obtained by contacting, NT Pharma Canada Limited at:

1-800-268-4127 ext 5005 (English)

1-877-777-9117 (French)

or druginfo@tevacanada.com

NT Pharma Canada Limited.

5691 Main Street

Stouffville, Ontario

Canada, L4A 1H5

Last revised: December 22, 2011

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02358980

Revision date stated in the text: December 22, 2011

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for NTP-Hydrochlorothiazide

Rx or OTC
Prescription (Rx)?
DIN 02358980, 02358999
Schedule(s) PRESCRIPTION
Active ingredient(s) Hydrochlorothiazide
Dosage form(s) Tablet
Route(s) of administration Oral
Drug class (WHO ATC)
  1. C Cardiovascular system drugs
    1. C03 Diuretics
      1. C03A Low-ceiling diuretics, thiazides
        1. C03AA Thiazides, plain
          1. C03AA03 Hydrochlorothiazide
Company TEVA CANADA LIMITED
Current status Cancelled Pre Market
Current status date March 16, 2017
Strengths and forms
DIN Strength Dosage form(s) Current status
02358980 25 MG Tablet Cancelled Pre Market March 16, 2017
02358999 50 MG Tablet Cancelled Pre Market March 16, 2017

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.